Charles River Laboratories International Inc. has announced a significant milestone in the development of gene therapy for rare diseases, as part of a collaborative effort with Elly's Team, a parent-led foundation. The partnership has successfully navigated the Food and Drug Administration (FDA) approval process, receiving Investigational New Drug $(IND.AU)$ approval in March 2025. This approval enabled the first administration of IRF2BPL gene replacement therapy to a child named Elly on April 3, 2025. This achievement is a result of combined efforts and expertise from multiple organizations, including Charles River, which provided critical support in manufacturing and advisory services. The collaboration marks a pivotal moment for the IRF2BPL community, offering hope and a path to treatment for families facing similar diagnoses.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。